Psychopharmacologia
May 28, 1976
B A Peters, E G Lewis, R E Dustman et al.
Three dose levels, 0.2, 0.4, and 0.6 mg/kg, of delta9-tetrahydrocannabinol (THC) and a placebo were orally administered to 10 frequent and 10 occasional marijuana users. Following ingestion of each dose and the placebo, objective tests selected from a battery of sensory and perceptual motor tests routinely used to evaluate cerebral dysfunction in hospitalized patients were administered. The...
Psychopharmacologia
April 15, 1976
O F Bueno, E A Carlini, E Finkelfarb et al.
Three groups of rats (A, B, C) were trained in a T-maze discriminate between drug-and control solution-induced internal discriminative stimuli. The drugs used to induce discriminative stimuli were: delta 9-THC, 5.0 mg/kg (Group A); ethanol, 1.2 g/kg (Group B), and amphetamine, 1.0 mg/kg(Group C). After discrimination acquisition several drugs were tested for generalization in each group. Group...
Psychopharmacologia
April 15, 1976
P G Waser, A Martin, L Heer-Carcano
The course of active avoidance learning of rats in a symmetrical Y-maze under the influence of 1, 3, and 9 mg/kg of delta 9-THC i.p., and 5, 20, and mug/kg of LSD was investigated. Delta-THC in a dosage of 1 mg/kg had no effect on avoidance learning. Three to a lesser extent 9 mg/kg produced more rapid learning with a significantly better performance. Learning under delta 9-THC proved to be...
Psychopharmacologia
September 1, 1970
W. R. Martin, J. W. Sloan
Tryptamine, infused intravenously in man, facilitates the patellar reflex, dilates pupils and elevates blood pressure. It also causes changes in vision and hearing, as well as nausea, vomiting, dizziness, sweating and heaviness of body. These changes are similar to those produced by LSD-like hallucinogens and are consistent with the hypothesis that LSD-like hallucinogens interact with...